There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Viking Therapeutics (VKTX – Research Report), Acrivon Therapeutics, Inc. (ACRV – Research Report) and Gain Therapeutics (GANX – Research Report) with bullish sentiments.
Viking Therapeutics (VKTX)
In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Viking Therapeutics, with a price target of $90.00. The company’s shares closed last Wednesday at $65.07.
According to TipRanks.com, Pantginis is a 4-star analyst with an average return of
Currently, the analyst consensus on Viking Therapeutics is a Strong Buy with an average price target of $113.50.
See Insiders’ Hot Stocks on TipRanks >>
Acrivon Therapeutics, Inc. (ACRV)
In a report released today, Emily Bodnar from H.C. Wainwright maintained a Buy rating on Acrivon Therapeutics, Inc., with a price target of $20.00. The company’s shares closed last Wednesday at $9.50.
According to TipRanks.com, Bodnar is a 3-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Acrivon Therapeutics, Inc. with a $21.14 average price target, which is an 116.2% upside from current levels. In a report issued on April 22, JonesTrading also maintained a Buy rating on the stock with a $26.00 price target.
Gain Therapeutics (GANX)
In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Gain Therapeutics, with a price target of $9.00. The company’s shares closed last Wednesday at $3.19.
According to TipRanks.com, Selvaraju is a 4-star analyst with an average return of
Gain Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $9.50, which is a 168.4% upside from current levels. In a report issued on April 23, Oppenheimer also maintained a Buy rating on the stock with a $9.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on VKTX:
- Viking Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
- Viking Therapeutics management to meet virtually with Truist
- VKTX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- LLY, VKTX, or NVO: Which Weight-Loss Drugmaker Could Gain the Best Returns?
- Viking Therapeutics Stock (NASDAQ:VKTX): Analysts Stay Bullish on 2024’s Top Mid-Cap
